Abstract
Recent clinical studies have demonstrated the capacity of immunosuppressive therapy to delay progression of inflammatory insulitis in type 1 diabetes (T1D). The procedure includes depletion of pathogenic cells by immunosuppressive therapy and support of recovery by reinfusion of autologous hematopoietic progenitors. The short-term outcome of these clinical transplants is similar to the predictions drawn from NOD mice: debulking of diabetogenic cells is ineffectively achieved by immunosuppressive therapy, and resetting of immune homeostasis does not restrain autoimmunity. Murine models indicate that allogeneic transplants are potentially curative, through restored mechanisms of negative regulation that are effective in continuous and indefinite suppression of autoimmunity.
Keywords: Activation induced cell death, autoimmunity, Fas cross-linking, inflammation, regulatory T cells.
Current Stem Cell Research & Therapy
Title:Hematopoietic Transplants for Disease Suppression and Cure in Type 1 Diabetes
Volume: 8 Issue: 4
Author(s): Nadir Askenasy
Affiliation:
Keywords: Activation induced cell death, autoimmunity, Fas cross-linking, inflammation, regulatory T cells.
Abstract: Recent clinical studies have demonstrated the capacity of immunosuppressive therapy to delay progression of inflammatory insulitis in type 1 diabetes (T1D). The procedure includes depletion of pathogenic cells by immunosuppressive therapy and support of recovery by reinfusion of autologous hematopoietic progenitors. The short-term outcome of these clinical transplants is similar to the predictions drawn from NOD mice: debulking of diabetogenic cells is ineffectively achieved by immunosuppressive therapy, and resetting of immune homeostasis does not restrain autoimmunity. Murine models indicate that allogeneic transplants are potentially curative, through restored mechanisms of negative regulation that are effective in continuous and indefinite suppression of autoimmunity.
Export Options
About this article
Cite this article as:
Askenasy Nadir, Hematopoietic Transplants for Disease Suppression and Cure in Type 1 Diabetes, Current Stem Cell Research & Therapy 2013; 8 (4) . https://dx.doi.org/10.2174/1574888X113089990001
DOI https://dx.doi.org/10.2174/1574888X113089990001 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The First Approved Agent in the Glitazar’s Class: Saroglitazar
Current Drug Targets NF-κB in Type 1 Diabetes
Inflammation & Allergy - Drug Targets (Discontinued) Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets Long-lasting Insulin Treatment Via a Single Subcutaneous Administration of Liposomes in Thermoreversible Pluronic® F127 Based Hydrogel
Current Pharmaceutical Design Diabetes and its Complications - Contemporary Treatment and Potential Side Effects of Drugs to Treat Diabetes
Current Drug Safety Managing Hypoglycemia in Diabetes May Be More Fear Management Than Glucose Management: A Practical Guide for Diabetes Care Providers
Current Diabetes Reviews Hyperglycemic Hyperosmolar State: A Pragmatic Approach to Properly Manage Sodium Derangements
Current Diabetes Reviews Can Diabetes Heal?- From Observations to Perspectives
Current Diabetes Reviews Perceptions in Type 1 Diabetes Mellitus with or Without the Use of Insulin Pump: An Online Study
Current Diabetes Reviews Editorial [Hot Topic:Continuous Glucose Monitoring Systems: Toys or Tools (Guest Editor: Christophe De Block)]
Current Diabetes Reviews The Heme Oxygenase System and Type-1 Diabetes
Current Pharmaceutical Design Herbal Drugs for Diabetic Treatment: An Updated Review of Patents
Recent Patents on Anti-Infective Drug Discovery Opportunities for Nano-Formulations in Type 2 Diabetes Mellitus Treatments
Current Pharmaceutical Biotechnology More Effective DPP4 Inhibitors as Antidiabetics Based on Sitagliptin Applied QSAR and Clinical Methods
Current Computer-Aided Drug Design Contemporary Roles of the Pediatric Psychologist in Diabetes Care
Current Diabetes Reviews Efficacy and Cardiovascular Safety of DPP-4 Inhibitors
Current Drug Safety Activated T Lymphocytes in Type 2 Diabetes: Implications From in Vitro Studies
Current Drug Targets Point-of-Care Testing in Diabetes Care
Mini-Reviews in Medicinal Chemistry Drugs and Rhabdomyolysis: From Liver to Kidney
Current Vascular Pharmacology Treatment Strategies Against Diabetic Foot Ulcer: Success so Far and the Road Ahead
Current Diabetes Reviews